Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

ALX Oncology Holdings stock

ALXO
US00166B1052
A2P79Z

Price

1.54
Today +/-
+0.09
Today %
+6.02 %

ALX Oncology Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ALX Oncology Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ALX Oncology Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ALX Oncology Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ALX Oncology Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ALX Oncology Holdings Stock Price History

DateALX Oncology Holdings Price
12/16/20241.54 undefined
12/13/20241.45 undefined
12/12/20241.42 undefined
12/11/20241.51 undefined
12/10/20241.58 undefined
12/9/20241.72 undefined
12/6/20241.62 undefined
12/5/20241.81 undefined
12/4/20241.56 undefined
12/3/20241.55 undefined
12/2/20241.66 undefined
11/29/20241.48 undefined
11/27/20241.51 undefined
11/26/20241.49 undefined
11/25/20241.47 undefined
11/22/20241.41 undefined
11/21/20241.29 undefined
11/20/20241.21 undefined
11/19/20241.23 undefined
11/18/20241.22 undefined

ALX Oncology Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ALX Oncology Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ALX Oncology Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ALX Oncology Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ALX Oncology Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ALX Oncology Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ALX Oncology Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ALX Oncology Holdings’s growth potential.

ALX Oncology Holdings Revenue, EBIT and net profit per share

DateALX Oncology Holdings RevenueALX Oncology Holdings EBITALX Oncology Holdings Net Income
2029e259.28 M undefined-14.95 M undefined122.11 M undefined
2028e156.18 M undefined-92.84 M undefined9.15 M undefined
2027e54.4 M undefined-169.97 M undefined-152.24 M undefined
2026e3.52 M undefined-176.85 M undefined-126.96 M undefined
2025e0 undefined-150.76 M undefined-134.7 M undefined
2024e0 undefined-145.48 M undefined-148.26 M undefined
20230 undefined-170.28 M undefined-160.81 M undefined
20220 undefined-127.44 M undefined-123.48 M undefined
20210 undefined-83.56 M undefined-83.46 M undefined
20201.18 M undefined-43.66 M undefined-50.94 M undefined
20194.8 M undefined-19.18 M undefined-23.27 M undefined
20182.07 M undefined-13.68 M undefined-17.4 M undefined

ALX Oncology Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
24100000354156259
-100.00-75.00------1,700.00188.8966.03
------------
000000000000
-17-23-50-83-123-160-148-134-126-1529122
-35.29117.3966.0048.1930.08-7.50-9.46-5.9720.63-105.921,255.56
34.7134.7118.4940.3140.742.99000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The ALX Oncology Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ALX Oncology Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
8.39434.2363.7266.2182.74
9005000000
000000
000000
10.31.83.44.84.92
10.29.8436367.1271187.66
10.90.13.49.810.84
000016.735.41
000000
000000
000000
0009.897.64
10.90.113.235.553.89
11.210.7436.1380.3306.5241.55
           
60.970.40000.05
1.72.1548.3565589.7675.68
-53.5-72.8-118.5-202-325.5-486.27
0000-800256
000000
9.1-0.3429.8363263.4189.71
0.73.703.88.18.59
0.91611.119.826.05
3002002000200630
000000
000400300728
1.94.96.215.328.436
05.400.39.411.21
000000
0.10.501.65.35.63
0.15.901.914.716.84
210.86.217.243.152.84
11.110.5436380.2306.5242.55
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ALX Oncology Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ALX Oncology Holdings's financial health and stability.

Assets

ALX Oncology Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ALX Oncology Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ALX Oncology Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ALX Oncology Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-13-19-45-83-123-160
000000
000000
040-498
0012334747
000001,000
000000
-13-14-38-68-89-130
000-4-1-1
000-4-23544
0000-23345
000000
050090
09473200
0154622959
00-100058
000000
-130425-70-314-26
-13.84-14.6-38.32-73.02-90.65-131.64
000000

ALX Oncology Holdings stock margins

The ALX Oncology Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ALX Oncology Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ALX Oncology Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ALX Oncology Holdings's sales revenue. A higher gross margin percentage indicates that the ALX Oncology Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ALX Oncology Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ALX Oncology Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ALX Oncology Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ALX Oncology Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ALX Oncology Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ALX Oncology Holdings Margin History

ALX Oncology Holdings Gross marginALX Oncology Holdings Profit marginALX Oncology Holdings EBIT marginALX Oncology Holdings Profit margin
2029e9.32 %-5.77 %47.1 %
2028e9.32 %-59.45 %5.86 %
2027e9.32 %-312.42 %-279.84 %
2026e9.32 %-5,025.55 %-3,607.72 %
2025e9.32 %0 %0 %
2024e9.32 %0 %0 %
20239.32 %0 %0 %
20229.32 %0 %0 %
20219.32 %0 %0 %
20209.32 %-3,700 %-4,316.95 %
20199.17 %-399.58 %-484.79 %
20189.18 %-660.87 %-840.58 %

ALX Oncology Holdings Stock Sales Revenue, EBIT, Earnings per Share

The ALX Oncology Holdings earnings per share therefore indicates how much revenue ALX Oncology Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ALX Oncology Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ALX Oncology Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ALX Oncology Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ALX Oncology Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ALX Oncology Holdings Revenue, EBIT and net profit per share

DateALX Oncology Holdings Sales per ShareALX Oncology Holdings EBIT per shareALX Oncology Holdings Earnings per Share
2029e4.92 undefined0 undefined2.32 undefined
2028e2.96 undefined0 undefined0.17 undefined
2027e1.03 undefined0 undefined-2.89 undefined
2026e0.07 undefined0 undefined-2.41 undefined
2025e0 undefined0 undefined-2.55 undefined
2024e0 undefined0 undefined-2.81 undefined
20230 undefined-3.96 undefined-3.74 undefined
20220 undefined-3.13 undefined-3.03 undefined
20210 undefined-2.07 undefined-2.07 undefined
20200.06 undefined-2.36 undefined-2.76 undefined
20190.14 undefined-0.55 undefined-0.67 undefined
20180.06 undefined-0.39 undefined-0.5 undefined

ALX Oncology Holdings business model

ALX Oncology Holdings Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. The company was founded in 2015 and is headquartered in Burlingame, California. It is listed on the NASDAQ stock exchange under the ticker symbol "ALXO." History ALX Oncology Holdings Inc was founded by Therese S. Wagner, a respected oncologist with extensive experience in cancer research. The company began its activities with a strong vision focused on developing targeted and effective treatments for cancer patients. Business Model ALX Oncology Holdings Inc is working on the development of immunotherapy products based on two mechanisms of action - inhibition of the CD47 molecule and activation of the myeloid cells of the immune system. The goal is to eliminate cancer cells by enabling them to be recognized and attacked by the immune system. This business model has the potential to improve both the effectiveness and versatility of cancer treatment. Divisions ALX Oncology Holdings Inc operates in several areas, including: Main products: • ALX148 - A monoclonal antibody that acts as a CD47 inhibitor • ALX148-Bispecifics - Two binding domains that contribute to the activation of the myeloid cells of the immune system In addition, ALX Oncology Holdings Inc collaborates with various partners to develop new drugs and therapies. These partnerships include both academic institutions and pharmaceutical companies. Products ALX148 is the flagship product of ALX Oncology. It is a monoclonal antibody that inhibits the CD47 molecule found on the surface of cancer cells, preventing their recognition by the immune system. By inhibiting CD47, the immune system can recognize and destroy cancer cells. ALX148-Bispecifics are antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) that have been developed to activate the myeloid cells in the immune system by combining CD47 inhibitory capabilities with the activation of macrophage-associated ligands (CD40 and CD80). This results in a stronger immune response to cancer cells, leading to their destruction. Summary ALX Oncology Holdings Inc is a biotechnology company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. Their products, ALX148 and ALX148-Bispecifics, inhibit the CD47 molecule and activate the immune system to fight cancer cells. The company collaborates with various partners and has the potential to provide new hope for people with cancer. ALX Oncology Holdings is one of the most popular companies on Eulerpool.com.

ALX Oncology Holdings SWOT Analysis

Strengths

ALX Oncology Holdings Inc has several notable strengths that contribute to its success and competitive advantage in the oncology industry. These strengths include:

  • Strong Research and Development Capabilities: ALX Oncology has a highly skilled and experienced research and development team, allowing them to continuously innovate and develop new oncology treatments.
  • Robust Pipeline: The company has a diverse and promising pipeline of potential oncology drugs, providing potential for future growth and revenue generation.
  • Strategic Partnerships: ALX Oncology has established strategic partnerships with leading pharmaceutical companies, enabling access to necessary resources, expertise, and distribution channels.
  • Strong Financial Position: With solid financial backing and significant funding, ALX Oncology is well-positioned to support its research, development, and commercialization efforts effectively.

Weaknesses

Despite its strengths, ALX Oncology Holdings Inc also encounters some weaknesses that could hinder its growth and market positioning. These weaknesses include:

  • Dependency on Drug Development Success: The company's revenue heavily relies on the successful development and approval of their oncology drugs. Any setbacks or failures in clinical trials could have a significant impact on financial performance.
  • Limited Market Presence: ALX Oncology's market presence is currently limited to specific geographic regions and specific oncology indications. Expanding to a broader market may pose challenges.
  • Relatively Small Scale: Compared to some larger competitors, ALX Oncology operates on a smaller scale, which may affect its ability to compete for resources or secure favorable partnerships.

Opportunities

ALX Oncology Holdings Inc can leverage various opportunities to further strengthen its market position and achieve business growth. These opportunities include:

  • Increasing Demand for Oncology Treatments: The rising global prevalence of cancer and the growing demand for effective oncology treatments presents a significant opportunity for ALX Oncology to expand its market reach.
  • New Partnerships and Collaborations: Forming strategic alliances with other biotechnology companies, healthcare providers, or academic institutions can enhance ALX Oncology's capabilities, broaden its pipeline, and lead to innovative breakthroughs.
  • Advancements in Technology: Integration of advanced technologies, such as precision medicine and targeted therapies, can enhance the efficacy and safety of ALX Oncology's drug candidates, attracting greater interest from patients and healthcare professionals.
  • Expanding Global Market: Exploring international markets, especially in regions with a high cancer burden and limited treatment options, can open up new revenue streams and increase ALX Oncology's market share.

Threats

ALX Oncology Holdings Inc faces several threats that could impact its business operations and overall success. Some of the major threats include:

  • Intense Competition: The oncology industry is highly competitive, with numerous established pharmaceutical companies and emerging biotech startups competing for market share and limited resources.
  • Regulatory Challenges: Stringent regulations and requirements imposed by regulatory bodies can result in delays and additional costs in obtaining drug approvals and commercializing products.
  • Economic Factors: Economic downturns, recessions, or changes in healthcare funding could potentially affect the affordability and accessibility of ALX Oncology's treatments, thereby impacting demand.
  • Emerging Technologies and Therapies: Rapid advancements and breakthroughs in alternative treatment modalities, such as immunotherapy or gene therapy, pose a threat by potentially displacing traditional oncology treatments.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ALX Oncology Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ALX Oncology Holdings historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ALX Oncology Holdings shares outstanding

The number of shares was ALX Oncology Holdings in 2023 — This indicates how many shares 42.988 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ALX Oncology Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ALX Oncology Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ALX Oncology Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ALX Oncology Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for ALX Oncology Holdings.

ALX Oncology Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.8 -0.58  (27.1 %)2024 Q3
6/30/2024-0.79 -0.76  (3.65 %)2024 Q2
3/31/2024-0.85 -0.71  (16.8 %)2024 Q1
12/31/2023-0.86 -0.93  (-8.35 %)2023 Q4
9/30/2023-0.89 -1.24  (-39.73 %)2023 Q3
6/30/2023-0.9 -0.84  (6.42 %)2023 Q2
3/31/2023-0.82 -0.74  (9.52 %)2023 Q1
12/31/2022-0.9 -0.75  (17.03 %)2022 Q4
9/30/2022-0.79 -0.87  (-10.69 %)2022 Q3
6/30/2022-0.65 -0.81  (-25.35 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the ALX Oncology Holdings stock

Eulerpool World ESG Rating (EESG©)

75/ 100

🌱 Environment

80

👫 Social

91

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ALX Oncology Holdings shareholders

%
Name
Stocks
Change
Date
18.39197 % VenBio Partners LLC9,699,92506/30/2024
14.72988 % Fidelity Management & Research Company LLC7,768,541262,4686/30/2024
8.00161 % Vivo Capital, LLC4,220,04806/30/2024
7.66174 % Tang Capital Management, LLC4,040,8004,040,8008/12/2024
7.65349 % Redmile Group, LLC4,036,451-290,0586/30/2024
6.82594 % Vestal Point Capital, LP3,600,000990,0006/30/2024
5.59268 % Lightstone Ventures, L.P.2,949,580-1,259,3952/12/2024
4.47604 % BlackRock Institutional Trust Company, N.A.2,360,662425,8866/30/2024
4.13512 % MPM BioImpact LLC2,180,864912,3936/30/2024
3.79669 % Millennium Management LLC2,002,374-959,2979/30/2024
1
2
3
4
5
...
10

ALX Oncology Holdings Executives and Management Board

Ms. Shelly Pinto

(47)
ALX Oncology Holdings Chief Accounting Officer, Vice President - Finance
Compensation 7.12 M

Dr. Jaume Pons

(57)
ALX Oncology Holdings President, Chief Scientific Officer (since 2015)
Compensation 3.73 M

Dr. Sophia Randolph

(55)
ALX Oncology Holdings Chief Medical Officer, Director (since 2016)
Compensation 2.08 M

Mr. Peter Garcia

(61)
ALX Oncology Holdings Chief Financial Officer
Compensation 1.75 M

Dr. Itziar Canamasas

(49)
ALX Oncology Holdings Independent Director
Compensation 326,747
1
2

Most common questions regarding ALX Oncology Holdings

What values and corporate philosophy does ALX Oncology Holdings represent?

ALX Oncology Holdings Inc represents a dedication to advancing innovative cancer therapies. The company's core values include excellence, integrity, and a commitment to improving patient outcomes. ALX Oncology strives to deliver transformative treatments for patients with difficult-to-treat cancers by leveraging its expertise in developing antibodies that target the CD47/SIRPα pathway. Through a patient-centered approach and a focus on scientific rigor, ALX Oncology is working tirelessly to redefine the standard of care in oncology. With its strong corporate philosophy and cutting-edge research, ALX Oncology Holdings Inc is poised to make significant contributions to the fight against cancer.

In which countries and regions is ALX Oncology Holdings primarily present?

ALX Oncology Holdings Inc is primarily present in the United States.

What significant milestones has the company ALX Oncology Holdings achieved?

ALX Oncology Holdings Inc, a leading oncology-focused biotechnology company, has achieved several significant milestones in recent years. The company has made remarkable progress in advancing its innovative pipeline of novel cancer therapies. One notable achievement includes the successful completion of a Phase 1 trial for ALX148, its lead product candidate. Furthermore, ALX Oncology has forged strategic collaborations and partnerships with renowned institutions and biopharmaceutical companies, which have both supported and accelerated its research and development efforts. These milestones demonstrate ALX Oncology's commitment to pioneering breakthrough therapies that have the potential to revolutionize cancer treatment and improve patient outcomes.

What is the history and background of the company ALX Oncology Holdings?

ALX Oncology Holdings Inc is a biotechnology company that focuses on developing innovative therapies for the treatment of cancer. The company was founded in [year] and is headquartered in [location]. ALX Oncology Holdings Inc has a rich history of scientific advancements and collaborations with leading research institutions. With a strong team of experienced industry professionals, the company has made significant progress in developing novel cancer treatments. ALX Oncology Holdings Inc is committed to improving the lives of cancer patients and aims to revolutionize the field of oncology with its innovative therapies.

Who are the main competitors of ALX Oncology Holdings in the market?

The main competitors of ALX Oncology Holdings Inc in the market include other companies specializing in the field of oncology. Some prominent competitors in the industry are Merck & Co., Inc., Bristol Myers Squibb Company, and Genentech, a member of the Roche Group. These companies also focus on developing innovative cancer treatments and therapies. ALX Oncology competes with these industry leaders by striving to differentiate itself through its unique approach, proprietary products, and research advancements in the field of oncology.

In which industries is ALX Oncology Holdings primarily active?

ALX Oncology Holdings Inc is primarily active in the biotechnology and healthcare industries.

What is the business model of ALX Oncology Holdings?

ALX Oncology Holdings Inc is a biopharmaceutical company focused on developing therapies for cancer treatment. Their business model revolves around the discovery and development of novel immunotherapies that target the CD47 checkpoint pathway. By leveraging their expertise in immune modulation, ALX Oncology aims to improve the outcomes for cancer patients by harnessing the power of the immune system to selectively target and eliminate tumor cells. Through diligent research and strategic collaborations, ALX Oncology strives to bring innovative therapies to market and make a meaningful impact in the field of oncology.

What is the P/E ratio of ALX Oncology Holdings 2024?

The ALX Oncology Holdings P/E ratio is -0.45.

What is the P/S ratio of ALX Oncology Holdings 2024?

The ALX Oncology Holdings P/S ratio is 0.

What is the Quality Investing of ALX Oncology Holdings?

The Quality Investing for ALX Oncology Holdings is 2/10.

What is the revenue of ALX Oncology Holdings 2024?

The revenue cannot currently be calculated for ALX Oncology Holdings.

How high is the profit of ALX Oncology Holdings 2024?

The expected ALX Oncology Holdings profit is -148.26 M USD.

What is the business model of ALX Oncology Holdings

ALX Oncology Holdings Inc is an emerging biotechnology company with a comprehensive portfolio of innovative cancer drugs currently in various stages of clinical development. The company is headquartered in Burlingame, California and is listed on the Nasdaq under the ticker symbol "ALXO". ALX Oncology Holdings Inc relies on a business model based on extensive scientific research and development. The company specializes in developing novel approaches to cancer treatment. ALX Oncology Holdings Inc investigates complex mechanisms contributing to cancer development and the interactions between tumor cells and the immune system. ALX Oncology Holdings Inc has developed a pipeline of drug candidates that represent potentially groundbreaking therapeutic approaches for various types of cancer. Most of these compounds target PD-L1, a protein produced by tumor cells that impairs the immune system. By blocking PD-L1, immune cells can better recognize and effectively combat the tumor. One of ALX Oncology Holdings Inc's leading drug candidates is ALX148, a specific antibody against PD-L1. ALX148 is currently in multiple clinical trials for various types of cancer in clinical development. The results of the initial studies are promising, and ALX Oncology Holdings Inc plans to obtain market approval for the drug in the coming years. In addition to ALX148, ALX Oncology Holdings Inc also has other drugs in its pipeline, such as ALX5641, which targets the inhibition of an enzyme crucial for the survival of tumor cells. Furthermore, ALX Oncology Holdings Inc is working on other compounds for cancer immunotherapy and the breakdown of immune barriers in the body. ALX Oncology Holdings Inc aims to collaborate with partners and other biopharmaceutical companies to distribute its cancer drug compounds in various markets and regions worldwide. For this purpose, ALX Oncology Holdings Inc works closely with clinical research organizations, regulatory authorities, and medical professionals to validate its products and pave the way for their approval. Overall, the business model of ALX Oncology Holdings Inc is closely connected to cancer research and development. It focuses on developing unique cancer drugs that target the blockade of specific signaling pathways in tumor cells. With a strong pipeline and a multitude of clinical trials, the company strives to develop new therapeutic approaches for severe types of cancer that can impact the lives of millions of people.

What is the ALX Oncology Holdings dividend?

ALX Oncology Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does ALX Oncology Holdings pay dividends?

The dividend cannot currently be calculated for ALX Oncology Holdings or the company does not pay out a dividend.

What is the ALX Oncology Holdings ISIN?

The ISIN of ALX Oncology Holdings is US00166B1052.

What is the ALX Oncology Holdings WKN?

The WKN of ALX Oncology Holdings is A2P79Z.

What is the ALX Oncology Holdings ticker?

The ticker of ALX Oncology Holdings is ALXO.

How much dividend does ALX Oncology Holdings pay?

Over the past 12 months, ALX Oncology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ALX Oncology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of ALX Oncology Holdings?

The current dividend yield of ALX Oncology Holdings is .

When does ALX Oncology Holdings pay dividends?

ALX Oncology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ALX Oncology Holdings?

ALX Oncology Holdings paid dividends every year for the past 0 years.

What is the dividend of ALX Oncology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ALX Oncology Holdings located?

ALX Oncology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALX Oncology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALX Oncology Holdings from 12/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did ALX Oncology Holdings pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of ALX Oncology Holdings in the year 2023?

In the year 2023, ALX Oncology Holdings distributed 0 USD as dividends.

In which currency does ALX Oncology Holdings pay out the dividend?

The dividends of ALX Oncology Holdings are distributed in USD.

All fundamentals about ALX Oncology Holdings

Our stock analysis for ALX Oncology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALX Oncology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.